secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2026-05-15T21:00:31+00:00
Accession:  0001104659-26-062766
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm Q1 net loss $2.1M; cash below $0.2M; NurOwn Phase 3 preparations ongoing
--------------------------------------------------------------------------------

- Net loss $2.1M ($0.19 per share) vs $2.9M ($0.45) in Q1 2025; operating loss $2.0M.
- Cash, equivalents, and restricted cash $0.2M at March 31, 2026, down from $0.3M at Dec 31, 2025.
- R&D expense $0.8M (down from $1.3M); G&A expense $1.3M (down from $1.8M).
- Planning Phase 3b ENDURANCE trial of NurOwn for ALS, targeting ~200 patients; BLA submission planned after Part A.
- Raised $2M via two private placements in Feb 2026; stockholders' deficit $11M; accounts payable $7.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/0001104659-26-062766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/tm2614771d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-062766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer